Literature DB >> 23395452

Targeted delivery of platinum-based anticancer complexes.

Jennifer S Butler1, Peter J Sadler.   

Abstract

The most widely used anticancer drugs are platinum-based. Their efficacy might be improved by carriers which can transport large numbers of Pt centres, shield the drug from premature activation, and/or deliver Pt specifically to cancer cells using vectors which recognise specific targets. We describe recent progress using functionalized carbon nanotubes (CNTs) and nanorods, hollow Prussian blue (HPB), magnetic iron oxide and gold nanoparticles, liposomes, nanogels and polymers, as well as active targeting by conjugation to biodegradable proteins and peptides (e.g. EGF, heparin, herceptin, somatostatin and TAT). Spatially targeted activation of Pt(IV) prodrugs using light is also a promising approach. Interestingly, use of these new delivery and targeting systems for platinum drugs can lead to species with unusual reactivity which can kill cancer cells by new mechanisms.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23395452     DOI: 10.1016/j.cbpa.2013.01.004

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  25 in total

Review 1.  Transporter and protease mediated delivery of platinum complexes for precision oncology.

Authors:  Trevor W Hambley
Journal:  J Biol Inorg Chem       Date:  2019-05-15       Impact factor: 3.358

2.  Labelling Herceptin with a novel oxaliplatin derivative: a computational approach towards the selective drug delivery.

Authors:  José P Cerón-Carrasco; Javier Cerezo; Alberto Requena; José Zuñiga; Julia Contreras-García; Sonali Chavan; Miguel Manrubia-Cobo; Horacio Pérez-Sánchez
Journal:  J Mol Model       Date:  2014-08-23       Impact factor: 1.810

Review 3.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

Review 4.  Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine.

Authors:  Chong Guo; Chaoying Song; Jiali Zhang; Yisong Gao; Yuying Qi; Zongyao Zhao; Chengfu Yuan
Journal:  Genes Dis       Date:  2020-12-01

5.  Investigation on Optical and Biological Properties of 2-(4-Dimethylaminophenyl)benzothiazole Based Cycloplatinated Complexes.

Authors:  Rebeca Lara; Gonzalo Millán; M Teresa Moreno; Elena Lalinde; Elvira Alfaro-Arnedo; Icíar P López; Ignacio M Larráyoz; José G Pichel
Journal:  Chemistry       Date:  2021-10-07       Impact factor: 5.020

6.  Linker design for the modular assembly of multifunctional and targeted platinum(ii)-containing anticancer agents.

Authors:  S Ding; U Bierbach
Journal:  Dalton Trans       Date:  2016-08-16       Impact factor: 4.390

7.  Cytotoxic potentials of biologically fabricated platinum nanoparticles from Streptomyces sp. on MCF-7 breast cancer cells.

Authors:  Balraj Baskaran; Arulmozhi Muthukumarasamy; Siva Chidambaram; Abimanyu Sugumaran; Krithikadevi Ramachandran; Thaneswari Rasu Manimuthu
Journal:  IET Nanobiotechnol       Date:  2017-04       Impact factor: 1.847

8.  Multifunctional αvβ6 Integrin-Specific Peptide-Pt(IV) Conjugates for Cancer Cell Targeting.

Authors:  Anne C Conibear; Sonja Hager; Josef Mayr; Matthias H M Klose; Bernhard K Keppler; Christian R Kowol; Petra Heffeter; Christian F W Becker
Journal:  Bioconjug Chem       Date:  2017-08-10       Impact factor: 4.774

9.  Synthesis and biological evaluation of biotin-conjugated Portulaca oleracea polysaccharides.

Authors:  Qianqian Han; Lirong Huang; Qiang Luo; Ying Wang; Mingliang Wu; Shixin Sun; Hongmei Zhang; Yanqing Wang
Journal:  RSC Adv       Date:  2021-05-19       Impact factor: 4.036

10.  Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin in vivo and in vitro.

Authors:  Tingting Lang; Nuannuan Li; Jing Zhang; Yi Li; Rong Rong; Yuanlei Fu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.